共 50 条
- [31] Combination of Chemotherapy and Gefitinib as First-Line Treatment of Patients with Advanced Lung Adenocarcinoma and Sensitive EGFR MutationsJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646Jin, BoNiu, YanjieZhang, YanweiChu, TianqingGu, AiqinPei, JunHan, Baohui
- [32] Evident clinical response to erlotinib as third-line treatment in EGFR FISH (+) male smoker patient with adenocarcinoma of lungAMERICAN JOURNAL OF CASE REPORTS, 2009, 10 : 169 - 174Krawczyk, PawelRemiszewski, WojciechCzekajska-Chehab, ElzbietaGryglicka, BeataWarda, EdwardPelak, MaciejWojas-Krawczyk, KamilaJankowska, OlgaMazurkiewicz, TomaszMilanowski, Janusz
- [33] Mutations in the EGFR gene as predictors of gefitinib-sensitivity specifically occur in lung adenocarcinoma patients with a relatively low exposure of tobacco smokingLUNG CANCER, 2005, 49 : S113 - S113Sugio, KUramoto, HHanagiri, TOyama, TYoshimatsu, TSugaya, MOno, KNakata, SMorita, MYasumoto, K
- [34] Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative studyBMC Cancer, 17Meng-Xia LiHao HeZhi-Hua RuanYu-Xi ZhuRong-Qing LiXiao HeBao-Hua LanZhi-Min ZhangGuo-Dong LiuHua-Liang XiaoYan WuBo ZhuGe WangZhen-Zhou Yang
- [35] Front-line treatment for advanced pulmonary adenocarcinoma based on EGFR mutation statusJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Wang, S.Yang, H.Ou, W.Fang, Q.
- [37] Erlotinib Treatment in Patients with Advanced Lung Adenocarcinoma with CISH-positive and CISH-negative EGFR Gene AlterationsANTICANCER RESEARCH, 2012, 32 (03) : 1107 - 1112Hou, Ming-MoHuang, Shiu-FengKuo, Han-PinYang, Cheng-TaTsai, Ying-HuangYu, Chih-TengLin, Horng-ChyuanChen, Chih-HungWang, Chih-LiangChung, Fu-TsaiHsieh, Jia-JuanHsu, ToddCheng, Hsin-YiOu, Li-YingWang, Hung-MingLin, Yung-ChangChang, Nai-JenChang, John Wen-Cheng
- [38] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutationsONCOLOGY LETTERS, 2017, 13 (06) : 4433 - 4444Krawczyk, PawelKowalski, Dariusz M.Ramlau, RodrygKalinka-Warzocha, EwaWiniarczyk, KingaStencel, KatarzynaPowrozek, TomaszReszka, KatarzynaWojas-Krawczyk, KamilaBryl, MaciejWojcik-Superczynska, MagdalenaGlogowski, MaciejBarinow-Wojewodzki, AleksanderMilanowski, JanuszKrzakowski, Maciej
- [39] A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutationsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Kim, D.Lee, S.Lee, J.Lee, M.Kang, J.Kim, S.Shin, S.Kim, H.Heo, D. S.
- [40] Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative studyBMC CANCER, 2017, 17Li, Meng-XiaHe, HaoRuan, Zhi-HuaZhu, Yu-XiLi, Rong-QingHe, XiaoLan, Bao-HuaZhang, Zhi-MinLiu, Guo-DongXiao, Hua-LiangWu, YanZhu, BoWang, GeYang, Zhen-Zhou